HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence

September 20, 2022

https://www.globenewswire.com/news-release/2022/09/20/2519228/0/en/HeartSciences-Granted-U-S-Patent-for-ECG-Assessment-of-Heart-Diastolic-Function-Using-Artificial-Intelligence.html

Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods. 

Read more at globenewswire.com

Related news for (HSCS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.